Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

Nitrofurazone: Target Organs and Levels of Evidence for TR-337

Toxicology and Carcinogenesis Studies of Nitrofurazone (CASRN 59-87-0) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
Peer Review DateRoute/Exposure LevelsStudy Laboratory
R: 0,310,620, M: 0,150,310 PPM/50 PER GROUP
Physiological Research Laboratory

Levels of Evidence

Male Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Preputial Gland: ADENOMA 8/50 8/50 2/50 OR CARCINOMA 1/50 8/50 5/50 COMBINED 9/50 16/50 7/50
  • Skin: SEBACEOUS GLAND ADENOMA 0/50 0/50 4/50; TRICHOEPITHELIOMA 0/50 0/50 1/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 0/50 7/50 2/50
Non-Neoplastic Lesions
  • TESTES: DEGENERATION 12/50 49/50 47/50
  • KNEE JOINT: DEGENERATION 5/50 32/50 48/50
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Mammary Gland: FIBROADENOMA 8/49 36/50 36/50
Non-Neoplastic Lesions
  • KNEE JOINT: DEGENERATION 4/49 30/50 39/50
Male Mice: No Evidence
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Ovary: GRANULOSA CELL TUMOR 1/47 4/50 9/50; BENIGN MIXED TUMORS 0/47 17/50 20/50
Non-Neoplastic Lesions
  • OVARY: ATROPHY 7/47 44/50 38/50